LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Policy LCD-L38985 · Oncology
New MolDX requires billing team review.
Code intelligence
R97.21 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code R97.21.
Elevated code riskView ICD-10 detail
Signal breakdown
1 shown · 1 total in platform
Risk: Elevated
0
Critical
0%
1
High
100%
0
Routine
0%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
Audit documentation
Building an audit file that includes R97.21?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription